Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06926374

Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery

Robotic assisted surgery has been performed for more than two decades with good success and safety profile. However, there was only one dominating robotic surgical system available in the past which led to high cost for robotic surgery. Recently, a new robotic surgical system (Sentire Robotic Surgical System) was introduced by researchers of The Chinese University of Hong Kong (CUHK). This new robotic surgical system aims to achieve similar outcomes and standards of robotic surgery performed using the dominating system but with a significantly lower cost. The technologic innovation and development of this new robotic system is made by the Cornerstone Robotics Limited, which is based in Hong Kong. In a pilot clinical study conducted at Prince of Wales Hospital involving 55 patients, the Sentire Robotic Surgical System had demonstrated high success rate with minimal complications in patients who underwent robotic colorectal, upper gastrointestinal, and urologic surgery. Researchers of CUHK would therefore like to conduct another prospective study to further evaluate the efficacy and safety of Sentire Surgical System C1000 in major gastrointestinal and urologic surgery with expanded indications. It is believed that the results of this study will provide data to support its use for wide range of procedures with minimal access trauma, for the benefit of patients. This system will also lead to a wider range of clinical application for minimally invasive surgery with a cost-effective model.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Colorectal Carcinoma Adenocarcinoma Biliary Tract Diseases Bladder Cancer Calculi Carcinoma Cholecystolithiasis Cholelithiasis Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Esophageal Cancer Esophageal Diseases Esophageal Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications GIST - Gastrointestinal Stromal Tumor Gallbladder Diseases Gallstones Gastric Cancer Gastrointestinal Diseases Gastrointestinal Neoplasms Gastrointestinal Stromal Tumors Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Head and Neck Neoplasms Hiatal Hernia With Gastroesophageal Reflux Disease Intestinal Diseases Intestinal Neoplasms Kidney Cancer Kidney Diseases Kidney Neoplasms Male Urogenital Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms, Glandular and Epithelial Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Pelvic Organ Prolapse Prolapse Prostate Cancer (Adenocarcinoma) Prostatic Diseases Prostatic Neoplasms Rectal Diseases Rectal Prolapse Stomach Diseases Stomach Neoplasms Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Prince of Wales Hospital, The Chinese University of Hong Kong

Hong Kong, China

Location status: Recruiting

Location contact

Simon SM Ng, MD

CONTACT

[email protected]

+852-35051495

About this study

As above.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

General Inclusion Criteria for All Procedures:

  • Body mass index <35 kg/m2
  • Suitable for the listed minimally invasive surgical procedures for treatment of respective diseases
  • Willingness to participate as demonstrated by giving informed consent

General Exclusion Criteria for All Procedures:

  • Contraindication to general anesthesia
  • Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention
  • Untreated active infection
  • Noncorrectable coagulopathy
  • Presence of another malignancy or distant metastasis
  • Emergency surgery
  • Vulnerable population (e.g., mentally disabled, pregnancy)

Robotic Colorectal Resection

Inclusion criteria

  • Adenocarcinoma or large adenoma (not amenable to endoscopic removal) located at the colorectum (from the cecum to the anal verge) amenable to minimally invasive surgery

Exclusion criteria

  • T4 tumor
  • Recurrent tumor
  • Extensive previous abdominal surgery precluding minimally invasive surgery

Robotic Transanal Total Mesorectal Excision

Inclusion criteria

  • Mid/low rectal adenocarcinoma located <12 cm from the anal verge

Exclusion criteria

  • T4 tumor or involvement of circumferential resection margin even after neoadjuvant therapy
  • Tumor requiring multivisceral resection
  • Tumor requiring abdominoperineal resection; recurrent rectal tumor
  • T1 tumor that can be treated by local excision
  • Extensive previous abdominal surgery

Robotic Rectopexy

Inclusion criteria

  • Clinically diagnosed with previously untreated and uncomplicated rectal prolapse or enterocele

Exclusion criteria

  • Extensive previous abdominal surgery precluding minimally invasive surgery

Radical Prostatectomy

Inclusion criteria

  • Clinically diagnosed with nonmetastatic adenocarcinoma of prostate

Exclusion criteria

  • Previous history of prostate surgery (e.g., transurethral resection of prostate)

Total or Partial Nephrectomy

Inclusion criteria

  • Clinically diagnosed with nonmetastatic kidney cancer

Exclusion criteria

  • Previous ipsilateral kidney surgery
  • Complex kidney anatomy (e.g., horseshoe kidney, complex renal vascular anatomy)

Radical Cystectomy

Inclusion criteria

  • Clinically diagnosed with nonmetastatic bladder cancer

Robotic Esophageal Hiatal Surgery and Fundoplication

Inclusion criteria

  • Clinically diagnosed with Hiatal Hernia and / or Gastroesophageal reflux disease amendable to fundoplication

Exclusion criteria

  • Previous history of laparotomy precluding minimally invasive surgery

Robotic Gastrectomy

Inclusion criteria

  • Clinical diagnosis of gastric tumor (Adenocarcinoma or Gastrointestinal Stromal Tumor (GIST)) amendable to minimally invasive radical gastrectomy

Exclusion criteria

  • Previous history of laparotomy precluding minimally invasive surgery

Robotic Esophagectomy

Inclusion criteria

  • Clinical diagnosis of carcinoma of esophagus amendable to minimally invasive esophagectomy

Exclusion criteria

  • Esophageal carcinoma after definitive chemoradiotherapy and indicated for salvage esophagectomy

Robotic Cholecystectomy

Inclusion criteria

  • Symptomatic gallbladder stones clinically indicated for laparoscopic cholecystectomy

Exclusion criteria

  • Acute cholecystitis
  • Previous history of abdominal surgery

Treatment and study plan

Robotic surgery using the Sentire Surgical System

Procedure

Robotic surgery using the Sentire Surgical System

Primary outcomes

  1. Conversion rate

    Time frame: Up to 1 month

    The definition of a conversion for this study is an emergent change in the treatment plan to conventional minimally invasive (laparoscopic/thoracoscopic) surgery (i.e., the use of more than one additional port), multiport robotic surgery, or to open surgery.

  2. Perioperative complications

    Time frame: Up to 1 month

    Perioperative complications including intraoperative complications and all complications occurring during the hospital stay or within 30 days after discharge will be graded according to the Clavien-Dindo classification. Complications of Clavien-Dindo grade III (those requiring surgical, endoscopic, or radiologic intervention) or above are regarded as major complications.

Secondary outcomes

  1. Operative time

    Time frame: Up to 1 month

  2. Operative blood loss

    Time frame: Up to 1 month

  3. Pain scores on a visual analog scale

    Time frame: Up to 1 month

  4. Analgesic requirement

    Time frame: Up to 1 month

  5. Length of hospital stay

    Time frame: Up to 1 month

  6. Resection margin positivity for malignancy

    Time frame: Up to 1 month

  7. Number of lymph nodes harvested

    Time frame: Up to 1 month

  8. Anal continence after surgery, measured by the Cleveland Clinic Incontinence Score (Wexner's Score)

    Time frame: Up to 12 months

    The Cleveland Clinic Incontinence Score or Wexner's Score is the most common score used to determine the severity of incontinence before and after surgery for anal incontinence. The scoring system takes into account the type and frequency of incontinence, and the extent to which it alters the patient's life. It consists of five questions to assess the degree of incontinence (solid, liquid, gas, wears pad, lifestyle alteration). The frequency of each type of incontinence is rated on a scale ranging from 0 (never) to 4 (always or to once a day) so that the sum of the frequencies add up to a total score that may range from 0 to 20. Higher scores indicate higher levels of incontinence.

  9. Male sexual function after surgery, measured by the International Index of Erectile Dysfunction - 5 (IIEF-5 questionnaire)

    Time frame: Up to 12 months

    IIEF-5 is an abridged five-item version of the 15-item International Index of Erectile Function (IIEF) which is used to diagnose the presence and severity of erectile dysfunction. This questionnaire consists of only five questions and each IIEF-5 item is scored on a five-point ordinal scale where lower values represent poorer sexual function. Thus, a response of 0 for a question is considered the least functional, whereas a response of 5 is considered the most functional. The possible scores for the IIEF-5 range from 1 to 25 (one question has scores of 1-5), and a score above 21 is considered as normal erectile function and at or below this cutoff, erectile dysfunction.

  10. Urinary function after surgery, measured by the International Prostate Symptom Score (IPSS)

    Time frame: Up to 12 months

    IPSS is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the patient to choose one out of six answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic).

Study contacts

Contact information is provided by the study sponsor or research team.

Simon SM Ng, MD

CONTACT

[email protected]

+852-35051495

Sponsors and collaborators

Lead sponsor

Chinese University of Hong Kong

Other

Registry information

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Apr 13, 2025
Registry last updated
Apr 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.